[go: up one dir, main page]

BRPI0806531A2 - Composto, composição farmacêutica, agente terapêutico, e, uso do composto. - Google Patents

Composto, composição farmacêutica, agente terapêutico, e, uso do composto.

Info

Publication number
BRPI0806531A2
BRPI0806531A2 BRPI0806531-4A2A BRPI0806531A BRPI0806531A2 BR PI0806531 A2 BRPI0806531 A2 BR PI0806531A2 BR PI0806531 A BRPI0806531 A BR PI0806531A BR PI0806531 A2 BRPI0806531 A2 BR PI0806531A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
therapeutic agent
therapeutic
agent
Prior art date
Application number
BRPI0806531-4A2A
Other languages
English (en)
Inventor
Tomoharu Iino
Hideki Jona
Jun Shibata
Tadashi Shimamura
Takeru Yamakawa
Lihu Yang
Original Assignee
Merck & Co Inc
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Banyu Pharma Co Ltd filed Critical Merck & Co Inc
Publication of BRPI0806531A2 publication Critical patent/BRPI0806531A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0806531-4A2A 2007-01-12 2008-01-08 Composto, composição farmacêutica, agente terapêutico, e, uso do composto. BRPI0806531A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88030207P 2007-01-12 2007-01-12
PCT/US2008/000221 WO2008088688A1 (en) 2007-01-12 2008-01-08 Substituted spirochromanone derivatives as acc inhibitors

Publications (1)

Publication Number Publication Date
BRPI0806531A2 true BRPI0806531A2 (pt) 2014-04-22

Family

ID=39297859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806531-4A2A BRPI0806531A2 (pt) 2007-01-12 2008-01-08 Composto, composição farmacêutica, agente terapêutico, e, uso do composto.

Country Status (27)

Country Link
US (1) US8093389B2 (pt)
EP (1) EP2111406B1 (pt)
JP (1) JP5319550B2 (pt)
KR (1) KR20090108022A (pt)
CN (1) CN101631791B (pt)
AR (1) AR064824A1 (pt)
AU (1) AU2008205638B2 (pt)
BR (1) BRPI0806531A2 (pt)
CA (1) CA2674573C (pt)
CL (1) CL2008000067A1 (pt)
CO (1) CO6190611A2 (pt)
CR (1) CR10944A (pt)
DO (1) DOP2009000176A (pt)
EC (1) ECSP099503A (pt)
GT (1) GT200900194A (pt)
HN (1) HN2009001276A (pt)
MA (1) MA31108B1 (pt)
MX (1) MX2009007502A (pt)
NI (1) NI200900139A (pt)
NZ (1) NZ577825A (pt)
PE (1) PE20081559A1 (pt)
RU (1) RU2009130736A (pt)
SG (1) SG177977A1 (pt)
TW (1) TW200836727A (pt)
UA (1) UA103990C2 (pt)
WO (2) WO2008088689A1 (pt)
ZA (1) ZA200904138B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910375B1 (en) * 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
WO2008088692A2 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives
US7946800B2 (en) 2007-04-06 2011-05-24 Brooks Automation, Inc. Substrate transport apparatus with multiple independently movable articulated arms
US8752449B2 (en) 2007-05-08 2014-06-17 Brooks Automation, Inc. Substrate transport apparatus with multiple movable arms utilizing a mechanical switch mechanism
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5435592B2 (ja) * 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
EP2310015A4 (en) * 2008-07-14 2011-10-26 Cropsolution Inc ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF
JP5689069B2 (ja) 2008-11-20 2015-03-25 ジェネンテック, インコーポレイテッド ピラゾロピリジンpi3k阻害剤化合物及び使用方法
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
EP3085402B1 (en) * 2009-12-31 2018-05-09 DEKA Products Limited Partnership Infusion pump assembley
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
CN101851237B (zh) * 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
PL2621493T3 (pl) 2010-09-30 2017-01-31 Pfizer Inc. N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
WO2012056372A1 (en) 2010-10-29 2012-05-03 Pfizer Inc. N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
WO2012077655A1 (ja) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Gpr119アゴニスト活性を有するスピロ誘導体
ES2573497T3 (es) 2011-02-02 2016-06-08 Vertex Pharmaceuticals Incorporated Pirrolopirazin-amidas de piperidina espirocíclicas como moduladores de canales iónicos
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
KR101567659B1 (ko) 2011-04-22 2015-11-09 화이자 인코포레이티드 아세틸-CoA 카복실라아제 억제제로 사용하기 위한 피라졸로스피로케톤 유도체
JPWO2012161119A1 (ja) * 2011-05-20 2014-07-31 興和株式会社 新規なスピロピペリジン誘導体及びこれを含有する医薬
BR112014018812A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para preparar os compostos i, composição agroquímica, método para combater fungos nocivos fitopagênicos, uso dos compostos de fórmula i e semente
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CN104220427A (zh) 2012-02-03 2014-12-17 巴斯夫欧洲公司 杀真菌嘧啶化合物
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
BR112015028214A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
MX2016002479A (es) 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
WO2018112204A1 (en) 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives
MX2019015849A (es) * 2017-06-30 2020-08-03 Quixgen Inc Nuevos compuestos de espirolactona.
MA71611A (fr) * 2022-07-29 2025-05-30 Pfizer Inc. Nouveaux inhibiteurs de l'acc

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814983A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Neue chromanon-derivate
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JPH03182725A (ja) 1989-12-08 1991-08-08 Internatl Business Mach Corp <Ibm> 非線形光学素子及びその製造方法
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DE69412067T2 (de) 1993-01-28 1999-03-25 Merck & Co., Inc., Rahway, N.J. Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US6017768A (en) 1994-05-06 2000-01-25 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5688997A (en) * 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
US5856083A (en) 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
AU705661B2 (en) 1995-06-06 1999-05-27 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002020509A2 (de) 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Arzneimittel gegen virale erkrankungen
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
HRP20040716A2 (en) 2002-02-27 2005-02-28 Pfizer Products Inc. Acc inhibitors
JP2005320250A (ja) 2002-05-09 2005-11-17 Ajinomoto Co Inc ビスラクトン誘導体及びその医薬組成物としての使用
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004092179A1 (ja) * 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US8138342B2 (en) 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
WO2006117669A1 (en) 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
EP1910375B1 (en) 2005-07-19 2011-05-11 Merck Sharp & Dohme Corp. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
US20090270435A1 (en) * 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
WO2008088692A2 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives

Also Published As

Publication number Publication date
GT200900194A (es) 2015-03-09
CA2674573A1 (en) 2008-07-24
DOP2009000176A (es) 2009-08-31
WO2008088688A1 (en) 2008-07-24
CA2674573C (en) 2015-04-14
UA103990C2 (en) 2013-12-25
US20080171761A1 (en) 2008-07-17
WO2008088689A1 (en) 2008-07-24
AU2008205638A1 (en) 2008-07-24
PE20081559A1 (es) 2008-11-20
CL2008000067A1 (es) 2008-05-16
RU2009130736A (ru) 2011-02-20
JP5319550B2 (ja) 2013-10-16
MX2009007502A (es) 2009-07-17
AU2008205638B2 (en) 2012-08-16
JP2010515733A (ja) 2010-05-13
CN101631791B (zh) 2012-12-12
EP2111406A1 (en) 2009-10-28
ECSP099503A (es) 2009-08-28
TW200836727A (en) 2008-09-16
ZA200904138B (en) 2010-04-28
HN2009001276A (es) 2012-01-17
NZ577825A (en) 2012-04-27
EP2111406B1 (en) 2012-10-24
MA31108B1 (fr) 2010-01-04
US8093389B2 (en) 2012-01-10
AR064824A1 (es) 2009-04-29
NI200900139A (es) 2010-02-24
CN101631791A (zh) 2010-01-20
CO6190611A2 (es) 2010-08-19
SG177977A1 (en) 2012-02-28
CR10944A (es) 2009-08-12
KR20090108022A (ko) 2009-10-14
HK1131136A1 (en) 2010-01-15

Similar Documents

Publication Publication Date Title
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0922435A2 (pt) &#34;composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso.&#34;
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BRPI0809656A2 (pt) Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0619911A2 (pt) composto, pró-droga, agente farmacêutico, e, uso do composto
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0816236A2 (pt) Peptídeo cdh3 e agente medicinal contendo o mesmo
BRPI1009392A2 (pt) &#34;formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica.&#34;

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BANYU PHARMACEUTICAL CO., LTD. (JP) , MERCK SHARP

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]